Laila Farhat
Internal Medicine · Brooklyn, NYNPI 1083786362
Payments from drug & device makers
Across 148 payments — averaging $23.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$435
- AbbVie$422
- Novo Nordisk$377
- Lilly USA, LLC$279
- Boehringer Ingelheim$277
- GSK$202
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,407100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $435 |
| AbbVie | 20 | $422 |
| Novo Nordisk | 8 | $377 |
| Lilly USA, LLC | 13 | $279 |
| Boehringer Ingelheim | 13 | $277 |
| GSK | 8 | $202 |
| Cumberland Pharmaceuticals, Inc. | 11 | $196 |
| Amgen | 10 | $186 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $157 |
| Abbott | 7 | $153 |
| Pfizer | 5 | $115 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $107 |
| Gilead | 4 | $85 |
| Mannkind Corporation | 4 | $83 |
| Vivus LLC | 1 | $71 |
| Exact Sciences | 3 | $69 |
| Merck | 3 | $50 |
| Kowa Pharmaceuticals America, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 2 | $23 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Vistapharm, Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$242
How this compares
$3,407 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 304 | $299,643 |
| OzempicSemaglutide | 228 | $225,945 |
| MounjaroTirzepatide | 176 | $215,839 |
| JanuviaSitagliptin Phosphate | 205 | $157,660 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 110 | $148,250 |
| LinzessLinaclotide | 178 | $116,079 |
| EliquisApixaban | 82 | $69,062 |
| FarxigaDapagliflozin Propanediol | 95 | $68,514 |
| JanumetSitagliptin Phos/Metformin Hcl | 56 | $50,804 |
| TrulicityDulaglutide | 32 | $47,318 |
| Breo ElliptaFluticasone/Vilanterol | 102 | $44,945 |
| XareltoRivaroxaban | 50 | $40,382 |
| Lactulose | 17 | $39,911 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 84 | $31,679 |
| Diclofenac Sodium | 202 | $31,086 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Spiriva Respimat | $277 | $351,826383 claims |
| Lilly USA, LLCMounjaro, Trulicity | $279 | $263,157208 claims |
| Novo NordiskOzempic | $377 | $225,945228 claims |
| MerckJanuvia, Janumet | $50 | $208,464261 claims |
| AbbVieLinzess | $422 | $116,079178 claims |
| AstraZenecaFarxiga, Brilinta | $435 | $82,569112 claims |
| GSKBreo Ellipta, Incruse Ellipta, Trelegy Ellipta | $202 | $76,677165 claims |
| PfizerEliquis | $115 | $69,06282 claims |
| Johnson & JohnsonXarelto | $19 | $40,38250 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Ambien | $18 | $32,26440 claims |
| AmgenProlia | $186 | $26,21816 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $107 | $11,86119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Brooklyn
- Bruce BergerBrooklyn$3.4M
- Nelly CohenBrooklyn$2.8M
- Jorge SerjeBrooklyn$1.3M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.